Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.63 |
| ▸ | CCR2 | P41597 | 9/20 | 0.63 |
| ▸ | TACR1 | P25103 | 10/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645885 | 1.00 | KCNH2 (0.63) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13645882 | 1.00 | KCNH2 (0.63) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13645891 | 0.88 | CCR2 (0.61) | KCNH2CCR2TACR1 | |
| SCHEMBL13650461 | 0.80 | KCNH2 (0.50) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL13646024 | 0.80 | CCR2 (0.55) | KCNH2CCR2TACR1 | |
| SCHEMBL18252874 | 0.80 | KCNH2 (0.48) | KCNH2CCR2TACR1CCR1 | |
| SCHEMBL5729653 | 0.79 | CCR2 (0.52) | KCNH2CCR2TACR1 | |
| SCHEMBL23938481 | 0.78 | KCNH2 (0.50) | KCNH2CCR2TACR1 | |
| SCHEMBL13887072 | 0.78 | KCNH2 (0.48) | KCNH2CCR2TACR1 | |
| SCHEMBL3616957 | 0.77 | CCR2 (0.56) | KCNH2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1622916-A4 | HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-11-05 | — | — | EP | disclosed |
| CN-100384856-C | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO INC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| EP-1318811-B1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1805965-A | Modulators of chemokine receptor activity | MERCK & CO INC (US) | 2006-07-19 | — | — | CN | disclosed |
| EP-1622916-A2 | HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004094371-A2 | HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1318811-A4 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1318811-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-04-25 | — | — | US | disclosed |
| WO-2002013824-A1 | CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049222-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR1, CCRL2, CCR5 | KCNH2 3123/4885CCR2 6/4885TACR1 52/4885 |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | KCNH2 2543/4885CCR2 3/4885TACR1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.